RESOURCES

/

FIND A SPECIALIST

/

CONTACT

Currently Enrolling
Observational

Protein in Urine

A Multicenter, Observational, Cross-sectional Study to estimate the Frequencies of APOL1 Genetic Variants, and explore kidney disease Biomarkers in Adult Black and African-American Patients with Proteinuric Kidney Disease.

Brief Description

Observational study that is one visit that after the Informed consent is signed, medical history is reviewed, and blood and urine specimens are collected. Optional genetic counseling is offered as well.

Email Phone
Site Name

AB Clinical Trials
2110 East Flamingo Road suite 103 Las Vegas, NV 89119

Sponsor

Maze Therapeutics

Study Drug

MZE829

Estimated enrollment

60

Estimated end date

May 2025

If there is not a site for a clinical trial nearby, you can ask the study team about the possibility of travel reimbursements (i.e., paying you back for your travel costs). Alternatively, you can ask about the possibility of participating from home.
Find other locations for this trial:
Currently Enrolling
Observational

Protein in Urine

A Multicenter, Observational, Cross-sectional Study to estimate the Frequencies of APOL1 Genetic Variants, and explore kidney disease Biomarkers in Adult Black and African-American Patients with Proteinuric Kidney Disease.

Brief Description

Observational study that is one visit that after the Informed consent is signed, medical history is reviewed, and blood and urine specimens are collected. Optional genetic counseling is offered as well.

Trial is for people with

18-65 year olds with moderate Proteinuria

Study Goal

To catch more patients of Black, African-American, Afro-Latino decent with kidney disease due to APOL1 Gene.

What is involved for the Patient?

Reading and signing of informed consent, review of medical history and medications, and collection of blood and urine samples.

About the drug or intervention

No intervention for this trial, but this is a trial if the patient tests APOL1 positive that they may be referred to

Find other locations for this trial:
Las Vegas, NV (AB Clinical Trials)
Frequently Asked Questions

Nephrotic Syndrome is not a disease itself, but rather a group of signs and symptoms that result from damage in the part of the kidney that filters blood (glomeruli).

Common symptoms include:

  • Foamy urine (called proteinuria) caused by protein “spilling” into the urine
  • Severe swelling in parts of the body, most noticeably around the eyes, hands, feet, and abdomen (called edema)
  • Weight gain due to a buildup of extra fluid
  • Fatigue
  • Loss of appetite
  • Low levels of protein in the blood (hypoalbuminemia)
  • Higher than normal fat and cholesterol levels in the blood (hyperlipidemia)

Nephrotic Syndrome can typically be diagnosed with a urine test.

Nephrotic Syndrome can be “primary” or “secondary” in nature.

Diseases that affect only the kidneys are called primary causes of Nephrotic Syndrome. Doctors often call these diseases “idiopathic,” which means that they arise from an unknown cause. Some of these diseases include:

  • Minimal Change Disease (MCD) – most common in children
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Membranous Nephropathy (MN) – most common in adults
  • IgA Nephropathy (IgAN)

Secondary Nephrotic Syndrome is caused by an underlying, systemic condition like diabetes, lupus, HIV, and others.

Clinical studies are any studies that involve people. There are two main types: observational and interventional. In an observational trial, researchers track health outcomes over time in groups of participants to look for patterns that help us better understand a disease. In an interventional trial, participants receive specific interventions, which can include new treatments or behavorial changes (e.g., diet changes). To learn more about clinical research, please visit the NephCure website.